en
svPress releases
Regulatory press release 2024-05-31
New number of shares and votes in Xspray Pharma after TO6
Press release 2024-05-24
Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib
Regulatory press release 2024-05-21
Bulletin from the annual general meeting of Xspray Pharma AB (publ), 21 May 2024
Regulatory press release 2024-05-20
Xspray Pharma appoints Chief Operating Officer and changes the Management Team
Regulatory press release 2024-05-08
Interim Report First Quarter 2024
Regulatory press release 2024-05-03
Xspray Pharma raises SEK 100.3 million through warrants TO6
Regulatory press release 2024-04-22
Xspray Pharma Announces Fourth Product Candidate, targeting USD 2.3 billion Market
Regulatory press release 2024-04-19
Xspray Pharma receives declaration of intent from Östersjöstiftelsen regarding exercise of TO6 warrants
Press release 2024-04-18
Important information to holders of warrants series TO6: subscription period begins today
Regulatory press release 2024-04-18